Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients (PGPC1)
A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer
Sponsor: Jazz Pharmaceuticals
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Jazz Pharmaceuticals
Other Metastatic Pancreatic Cancer trials with similar outcome
This PHASE2 trial investigates Metastatic Pancreatic Cancer and is currently terminated or withdrawn. Jazz Pharmaceuticals leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Nov 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Apr 2022 — Jul 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Dec 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jazz Pharmaceuticals
- Translational Drug Development
For direct contact, visit the study record on ClinicalTrials.gov .